One in Four: What Makes Life Sciences Companies So Vulnerable to Securities Class Actions

BioDech

BioDech
One in Four: What Makes Life Sciences Companies So Vulnerable to Securities Class Actions
Sep 14, 2023
Dechert LLP

Securities class actions are on the rise and life sciences organizations are of specific interest to regulators. In our sixth episode of BioDech, a global life sciences broadcast series, Joni Jacobsen, co-chair of the global securities and complex litigation team and Angela Liu, securities litigation partner are joined by Tiffany Engsell, Senior Counsel, Litigation & Government Investigations, Bristol Myers Squibb, to discuss securities fraud class actions against U.S. life sciences companies and what to look out for after your company becomes public.